Light probe could help surgeons spot brain tumors Mid-Operation
NCT ID NCT02473380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a special light probe that helps surgeons see brain tumor tissue during an operation. Eleven adults with suspected brain tumors took part. The probe uses a drug that makes tumor cells glow, and the goal was to see if the device could accurately tell tumor from healthy brain tissue in real time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 5-aminolevulinic acid (Gliolan) as a contrast agent
- What this could lead to
- If successful, this could lead to a real-time tool that helps surgeons remove brain tumors more precisely during surgery.
- What could go wrong
- This is a very early feasibility study with only 11 people. The technique may not work as well in living patients as it did in the lab, and it is not yet ready for widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
11 people
The number who actually took part.
- Start date
-
Aug 2015
- Finished
-
Oct 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients older than 18 years old * Clinical signs and history of the disease in favor of a HGG, LGG * MRI study in favor of a HGG, LGG, meningioma or brain metastasis * Affiliated to or beneficiary of a social security system (or equivalent). * Patients who have provided written informed consent for the study Exclusion Criteria: * Previous life-threatening allergic reactions and known hypersensitivity * Pregnant or lactating or not using effective contraception; * Restricted renal function define by a creatinine clearance \< 30ml/min * Patients under a beta-blockers treatment * Contraindication to do an MRI (pace-maker) * Contraindication to the use of 5-ALA : known hypersensibility to 5-ALA or to porphyrin, acute or chronic porphyria * Minor or adult ward of court (under guardianship or trusteeship) * No affiliation to a social security system (or equivalent). * Patients who express opposition to participation in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High-grade glioma (HGG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospices Civils de Lyon
Lyon, 69002, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.